Table 5.

Multivariable regression analysis in allo-HCT cohort

nHR95% CI, lower limit95% CI, upper limitPOverall P
NRM       
 Prior therapy regimens received, n       
  1 51 1    .01 
  2 27 1.38 0.52 3.63 .52  
  ≥3 30 4.05 1.75 9.39 <.001  
  Missing 6 0.96 0.12 7.59 .97  
Relapse*       
 Disease status       
  CR 40 1.00    <.001 
  PR 49 2.65 1.10 6.38 .03  
  Resistant 19 6.81 2.49 18.59 <.001  
  Missing 6 0.87 0.11 7.07 .90  
PFS*       
 Disease status       
  CR 40 1.00    <.001 
  PR 49 1.97 1.07 3.61 .03  
  Resistant 19 5.42 2.73 10.79 <.001  
  Missing 6 0.78 0.18 3.39 .74  
OS       
 Disease status       
  CR 40 1.00    <.001 
  PR 51 2.05 1.04 4.06 .04  
  Resistant 20 6.63 3.16 13.92 <.001  
  Missing 7 1.05 0.23 4.70 .95  
nHR95% CI, lower limit95% CI, upper limitPOverall P
NRM       
 Prior therapy regimens received, n       
  1 51 1    .01 
  2 27 1.38 0.52 3.63 .52  
  ≥3 30 4.05 1.75 9.39 <.001  
  Missing 6 0.96 0.12 7.59 .97  
Relapse*       
 Disease status       
  CR 40 1.00    <.001 
  PR 49 2.65 1.10 6.38 .03  
  Resistant 19 6.81 2.49 18.59 <.001  
  Missing 6 0.87 0.11 7.07 .90  
PFS*       
 Disease status       
  CR 40 1.00    <.001 
  PR 49 1.97 1.07 3.61 .03  
  Resistant 19 5.42 2.73 10.79 <.001  
  Missing 6 0.78 0.18 3.39 .74  
OS       
 Disease status       
  CR 40 1.00    <.001 
  PR 51 2.05 1.04 4.06 .04  
  Resistant 20 6.63 3.16 13.92 <.001  
  Missing 7 1.05 0.23 4.70 .95  
*

Histology at relapse (CLL/SLL vs DLBCL-RS) was not available; therefore, any relapse was considered an event.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal